Navigation Links
Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures
Date:12/16/2008

LOS GATOS, Calif., Dec. 16 /PRNewswire/ -- TriCipher will host an informative Webinar detailing the cost cutting capabilities of digital signatures for the pharmaceutical and health care industries and strategies for securing digital signatures as more business processes transition online. The one hour webinar on December 16th brings together executives from SAFE- BioPharma Association and Pfizer who will discuss how digital signatures have benefited and streamlined research processes.

"Digital signatures represent the 'last mile' in moving business processes online for the pharmaceutical and health care industries," said Jon Brody, vice president of marketing at TriCipher. "Through the work of industry associations like SAFE-BioPharma and enabling technology companies like TriCipher, it's now possible to bridge that gap."

    Participants that attend the Webinar will learn:

     --   How businesses have saved hundreds of thousands of dollars by no
          longer needing to handle paper-based signatures
     --   The benefits of streamlining submissions to FDA and other regulatory
          agencies
     --   Strategies for protecting intellectual property and delivering a
          long term solution to IP preservation
     --   The 'Green' benefits of digital signatures


     WHO:      Mollie Shields-Uehling, president and CEO, SAFE-BioPharma
               Association
               William Barnes, Director of Identity Services, Pfizer
               Jon Brody, vice president of marketing, TriCipher
               A managing director of identity services at a leading
               international systems integrator
     WHAT:     "Cutting Costs with Digital Signatures in the Biopharmaceutical
               Industry"
     WHEN:     Tuesday, December 16th, 11 a.m. - 12 p.m. PT
     WHERE:    To register please visit:
              https://www2.gotomeeting.com/register/792964500

The webinar will include a brief demonstration of digital signatures using TriCipher's MySignatureBook with SAFE-BioPharma credentials. For more information on MySignatureBook and the webinar, please visit http://www.Tricipher.com.

About TriCipher

TriCipher, Inc. provides a unified authentication infrastructure to protect web and enterprise portals, the people that use them and the business process that flows through them against fraud and identity theft. The TriCipher Armored Credential System(TM) (TACS) is the first authentication system that enables companies to deploy and manage multiple types of credentials from a single infrastructure. Through this flexible "Authentication Ladder," TriCipher protects customer investment by adjusting authentication strength to defeat new threats and to meet regulatory changes without the need to implement a new infrastructure. Recently, TriCipher introduced myOneLogin(TM) the first secure on-demand offering that delivers strong authentication, single sign-on (SSO) convenience and the ability to seamlessly integrate multiple Software as a Service (SaaS) applications in a single solution. Founded in 2000, TriCipher is headquartered in Los Gatos, Calif. The company is funded by ArrowPath Venture Capital, EPIC Ventures, Intel Capital, RBC Technology Ventures, and Trident Capital. For more information, visit TriCipher on the web at http://www.tricipher.com.

About MySignatureBook

TriCipher MySignatureBook(TM) is a web-based digital signing solution that gathers multiple signatures from a centrally managed, Web-based workflow to a single, unaltered document. MySignatureBook ensures end-to-end security for highly regulated and sensitive documents, and eliminates time-consuming and costly paper-based signature processes, including shipping and storage. MySignaureBook supports a range of MSB supports a variety of strong credentials, including TriCipher clientless credentials, SAFE(TM) credentials, TriCipher ID Tool and ID Tool ToGo and any PKCS#11 digital credential. A robust web services interface makes it easy to integrate MSB with a variety of applications and document management systems.

About SAFE-BioPharma Association

SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma(TM) digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma's vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association's members include Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, , Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, visit http://www.safe-biopharma.org.

SAFE-BioPharma(TM) is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

All product and company names herein may be trademarks of their registered owners.


'/>"/>
SOURCE TriCipher, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: